Related Experiment Video
Updated: Jun 3, 2026

An Enzymatic Method to Rescue Mesenchymal Stem Cells from Clotted Bone Marrow Samples
Published on: April 12, 2015
Zymogen Protein C to prevent clotting without bleeding during invasive medical procedures
Duane F Bruley1, Sanjay B Jagannath, Micheal B Streiff
1Synthesizer, Inc., 2773 Westminster Road, Ellicott City, MD 21043, USA. bruley@umbc.edu
Insights
Zymogen Protein C concentrate (ZPC) effectively managed a patient with protein C deficiency and a history of pulmonary embolism who experienced a gastrointestinal bleed. ZPC prevented thrombosis during a critical peri-procedural period.
Area of Science:
- Hematology
- Thrombosis and Hemostasis
- Pharmacology
Background:
- Thrombophilic disorders, such as Protein C deficiency, significantly increase the risk of Venous Thromboembolism (VTE), a leading cause of death.
- Protein C deficiency, affecting 1 in 400 Americans, results in approximately half the normal level of endogenous anticoagulant protein C.
- Patients with Protein C deficiency face a 10-fold increased risk of VTE compared to the general population.
Observation:
- A 75-year-old male with heterozygous Protein C deficiency and a history of pulmonary embolism developed a life-threatening gastrointestinal bleed post-polypectomy.
- The bleed occurred while transitioning anticoagulation from Low Molecular Weight Heparin (LMWH) bridge therapy to warfarin.
- Endoscopic intervention successfully controlled the acute bleeding episode.
Findings:
- Zymogen Protein C concentrate (ZPC) was administered to prevent thrombosis during the peri-procedural period when anticoagulation was interrupted.
- The patient received ZPC until anticoagulation with LMWH and warfarin could be safely resumed.
- Following endoscopic repair and resumption of anticoagulation, the patient remained free of both bleeding and thrombotic events for 16 months.
Implications:
- Zymogen Protein C concentrate (ZPC) is a viable therapeutic option for peri-procedural management in patients with Protein C deficiency and a history of thromboembolism.
- This case highlights the successful use of ZPC in preventing thrombosis in a high-risk patient undergoing an invasive procedure.
- Consideration of ZPC can mitigate the risks associated with managing anticoagulation in complex thrombophilic patients.
Abstract:
Thrombophilic disorders that predispose patients to develop blood clots can be life-threatening and result in a large economic burden on healthcare expenditures. Venous Thromboembolism(VTE) (deep vein thrombosis and pulmonary embolism) are the third leading cause of death in the United States. Protein C deficiency is a common thrombophilic condition that affects an estimated 1 in 400 Americans. Zymogen Protein C (ZPC) is the precursor to Activated Protein C (APC), a pivotal endogenous anticoagulant in human blood. Patients with protein C deficiency who have roughly half the normal level of protein C are estimated to be at 10-fold increased risk of VTE. We describe the use of protein C concentrate (Ceprotin®, Baxter, Deerfield, IL) in a patient with protein C deficiency and with a previous pulmonary embolism who developed a life-threatening gastrointestinal bleed after polypectomy. The patient is a 75-year-old male at very high risk for deep vein thrombosis and possible lung emboli. He has heterozygous Protein C deficiency (50%) and heterozygosity for the prothrombin gene G20210A mutation. During a routine colonoscopy, a large 3 cm cecal polyp was identified and resected. Eight days post-procedure while performing abdominal exercise he developed a life-threatening GI bleed originating from the polypectomy site as his warfarin was becoming therapeutic on a Low Molecular Weight Heparin (LMWH) periprocedural bridge. The patient's warfarin was reversed with vitamin K, and LMWH and warfarin were discontinued. To prevent thrombosis, he was started on ZPC until anticoagulation could be safely restarted. During endoscopy, the bleeding site was treated with an injection of 1:10,000 dilution of epinephrine, followed by cauterization and placement of endoclips (4 metal staples). Three days after endoscopic repair LMWH was restarted with warfarin. Sixteen months post-bleed, the patient remains on life-long warfarin without further episodes of bleeding or thrombosis. Zymogen Protein C concentrate (Ceprotin®, Baxter Deerfield, IL) should be strongly considered for peri-procedural management of any patient with protein C deficiency and previous thromboembolism.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clot Retraction and Fibrinolysis
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation
